The estimated Net Worth of Todd C Brady is at least $13.8 million dollars as of 9 March 2024. Todd Brady owns over 183,238 units of Aldeyra Therapeutics Inc stock worth over $9,107,335 and over the last 11 years he sold ALDX stock worth over $580,864. In addition, he makes $4,141,260 as President, Chief Executive Officer et Director at Aldeyra Therapeutics Inc.
Sign up
Todd Brady ALDX stock SEC Form 4 insiders trading
Todd has made over 13 trades of the Aldeyra Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 183,238 units of ALDX stock worth $580,864 on 9 March 2024.
The largest trade he's ever made was exercising 273,058 units of Aldeyra Therapeutics Inc stock on 7 September 2023 worth over $150,182. On average, Todd trades about 11,389 units every 65 days since 2013. As of 9 March 2024 he still owns at least 1,471,298 units of Aldeyra Therapeutics Inc stock.
You can see the complete history of Todd Brady stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Todd Brady biography
Dr. Todd C. Brady M.D. Ph.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Brady has served as our President and Chief Executive Officer since January of 2012 and as a member of our Board of Directors since 2005. Prior to Aldeyra, Dr. Brady served as Entrepreneur in Residence at Domain Associates, LLC, a leading healthcare venture capital firm, where he was a Principal from 2004 to 2013. Dr. Brady currently serves on the Board of Directors of Evoke Pharma, Inc. and Spring Bank Pharmaceuticals, Inc., both of which are publicly traded healthcare companies. Dr. Brady holds a Ph.D. in pathology from Duke University Graduate School, a M.D. from Duke University Medical School, and an A.B. from Dartmouth College in Philosophy and Psychology. Dr. Brady’s extensive knowledge of our business, as well as his years of experience in the biotechnology industry, including executive leadership in several biotechnology companies, contributed to our conclusion that he should serve as a director of our company.
What is the salary of Todd Brady?
As the President, Chief Executive Officer et Director of Aldeyra Therapeutics Inc, the total compensation of Todd Brady at Aldeyra Therapeutics Inc is $4,141,260. There are no executives at Aldeyra Therapeutics Inc getting paid more.
How old is Todd Brady?
Todd Brady is 48, he's been the President, Chief Executive Officer et Director of Aldeyra Therapeutics Inc since 2012. There are 9 older and 4 younger executives at Aldeyra Therapeutics Inc. The oldest executive at Aldeyra Therapeutics Inc is Jesse Treu, 73, who is the Independent Director.
What's Todd Brady's mailing address?
Todd's mailing address filed with the SEC is C/O EVOKE PHARMA, INC., 420 STEVENS AVENUE, SUITE 230, SOLANA BEACH, CA, 92075.
Insiders trading at Aldeyra Therapeutics Inc
Over the last 11 years, insiders at Aldeyra Therapeutics Inc have traded over $6,285,725 worth of Aldeyra Therapeutics Inc stock and bought 11,547,153 units worth $75,179,936 . The most active insiders traders include Advisors Llcperceptive Life..., & Johnson Johnson & Johnson... et Advisors Llcedelman Josephp.... On average, Aldeyra Therapeutics Inc executives and independent directors trade stock every 54 days with the average trade being worth of $1,358,662. The most recent stock trade was executed by Stephen Machatha on 12 August 2024, trading 16,041 units of ALDX stock currently worth $76,034.
What does Aldeyra Therapeutics Inc do?
dedicated to improving lives by developing products that treat aldehyde-mediated diseases. we are a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes. we are developing adx-102 (formerly ns2), as well as other novel product candidates that are designed specifically to sequester aldehydes, for the treatment of: • noninfectious anterior uveitis, a rare severe inflammatory eye disease that can lead to blindness; • allergic conjunctivitis, a common disease that affects more than 20% of the population worldwide, and related rare allergic ocular diseases that are characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in ocular itching, excessive tear production, swelling, and redness; • dry eye disease, a common inflammatory dise
What does Aldeyra Therapeutics Inc's logo look like?
Complete history of Todd Brady stock trades at Aldeyra Therapeutics Inc, Evoke Pharma Inc et Spring Bank Pharmaceuticals
Aldeyra Therapeutics Inc executives and stock owners
Aldeyra Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Todd Brady,
President, Chief Executive Officer, Director -
Joshua Reed,
Chief Financial Officer -
David McMullin,
Chief Commercial Officer -
Dr. Todd C. Brady M.D., Ph.D.,
CEO, Pres & Director -
Joshua Reed M.B.A.,
Chief Financial Officer -
Richard Douglas,
Independent Chairman of the Board -
Martin Joyce,
Independent Director -
Jesse Treu,
Independent Director -
Ben Bronstein,
Independent Director -
Gary Phillips,
Independent Director -
Neal Walker,
Independent Director -
Scott Solomon,
IR Contact Officer -
Nancy Miller-rich,
Independent Director -
Stephen Machatha,
Senior Vice President, Technical Operations -
James Gow,
Senior Vice President - Clinical Development -
Bruce Greenberg CPA, M.B.A.,
VP & Controller -
Dr. Stephen G. Machatha Ph.D.,
Chief Devel. Officer -
Kelly Mizer,
VP of Commercial Strategy & Operations -
David J Clark,
Chief Medical Officer -
Advisors Llcedelman Josephp...,
-
C. Boyd Clarke,
Director -
Stephen J Tulipano,
Chief Financial Officer -
Scott Young,
Chief Operating Officer -
Bruce Greenberg,
See Remarks -
Advisors Llcperceptive Life...,
-
Partners Vi, L.P.Blair Jame...,
-
& Johnson Johnson & Johnson...,
-
Vi Associates, L.P.Blair Ja...,